Generation of a CFTR knock-in reporter cell line (MHHi006-A-1) from a human induced pluripotent stem cell line

Engels, Lena; Olmer, Ruth; Göhring, Gudrun; Ulrich, Saskia; Haller, R; Merkert, Sylvia

doi:10.1016/j.scr.2019.101542

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is the most common life-limiting, autosomal recessive monogenic disease in Caucasian populations ( Farrell et al, 2008 ; Cantin et al, 2015 ). CFTR encodes an ion channel that is mainly expressed in the secretory epithelial cells of the airway, intestine, liver, and other tissues ( Engels et al, 2019 ). Although cystic fibrosis influences multiple organs, progressive airway remodelling, mucus accumulation, and chronic inflammation of the lung leading to respiratory failure are the major cause of morbidity and mortality ( Nuciforo and Heim, 2021 ).…”

Section: Gene-editing Ipscs In Basic and Translational Discovery For ...mentioning

confidence: 99%

Induced pluripotent stem cell-based therapies for organ fibrosis

Cheng,

Fan,

Song

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Fibrotic diseases result in organ remodelling and dysfunctional failure and account for one-third of all deaths worldwide. There are no ideal treatments that can halt or reverse progressive organ fibrosis, moreover, organ transplantation is complicated by problems with a limited supply of donor organs and graft rejection. The development of new approaches, especially induced pluripotent stem cell (iPSC)-based therapy, is becoming a hot topic due to their ability to self-renew and differentiate into different cell types that may replace the fibrotic organs. In the past decade, studies have differentiated iPSCs into fibrosis-relevant cell types which were demonstrated to have anti-fibrotic effects that may have the potential to inform new effective precision treatments for organ-specific fibrosis. In this review, we summarize the potential of iPSC-based cellular approaches as therapeutic avenues for treating organ fibrosis, the advantages and disadvantages of iPSCs compared with other types of stem cell-based therapies, as well as the challenges and future outlook in this field.

show abstract